{
    "clinical_study": {
        "@rank": "26770", 
        "arm_group": {
            "arm_group_label": "umbilical cord blood mononuclear cells", 
            "arm_group_type": "Experimental", 
            "description": "Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation."
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety and efficacy of umbilical cord blood mononuclear cells\n      transplantation in liver cirrhosis patients."
        }, 
        "brief_title": "Umbilical Cord Blood Mononuclear Cells Therapy in Liver Cirrhosis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Decompensated liver cirrhosis (LC), a life-threatening complication of chronic liver\n      disease, is one of the major indications for liver transplantation. Recently, umbilical cord\n      blood mononuclear cells transfusion has been shown to lead to the regression of liver\n      fibrosis in animal model. The investigators thus investigated the safety of the therapy with\n      life signs like temperature, pulse, blood pressure, the incidence of hepatocellular\n      carcinoma and mortality and so on. And the efficacy was evaluated with the measurement of\n      alanine aminotransferase (ALT), glutamic oxaloacetic transaminase (AST), total bilirubin\n      (TBIL), direct bilirubin (DBIL), albumin (ALB), cholinesterase (CHE), prothrombin time (PT)\n      and child-pugh score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with hepatocirrhosis: according to the standard of child- pugh, liver\n             functions to achieve class A or B patients, Including C class patients but can\n             achieve B class after treatment\n\n        Exclusion Criteria:\n\n          1. Patients with C class by child-pugh score\n\n          2. Patients in the acute phase of severe hepatitis\n\n          3. Patients have been diagnosed with cancer of the liver\n\n          4. Patients with severe cardiopulmonary cerebral disease, and in the failure state\n\n          5. Patients in Highly allergic constitution\n\n          6. Patients with moderately severe mental disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942915", 
            "org_study_id": "12276102D-Liver Cirrhosis"
        }, 
        "intervention": {
            "arm_group_label": "umbilical cord blood mononuclear cells", 
            "description": "Participants will be transplanted with umbilical cord blood mononuclear cells.", 
            "intervention_name": "Umbilical Cord Blood Mononuclear Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050000"
                }, 
                "name": "the First Hospital of Hebei Medical University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy Investigation of Patients With Liver Cirrhosis by Transplantation of Umbilical Cord Blood Mononuclear Cells", 
        "overall_official": [
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Baoyong Yan, doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Lixin Tong, master", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Sui Zhang, master", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Quanhai Li, doctor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "child-pugh A (child-pugh score 5-6)\nchild-pugh B (child-pugh score 7-9)\nchild-pugh C (child-pugh score\u226510)", 
            "measure": "child-pugh classification", 
            "safety_issue": "No", 
            "time_frame": "whinin 7 days before transplantation, 1,3 and 6 months after transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942915"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Quanhai Li", 
            "investigator_title": "Director of Cell Thearpy Center, the First Hospital of HeibeiMU", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "prothrombin time (PT)\nactivated partial thromboplastin time (APTT)\nfibrinogen (FIB)", 
                "measure": "coagulation", 
                "safety_issue": "Yes", 
                "time_frame": "whinin 7 days before transplantation, 1,3,6 months after transplantation"
            }, 
            {
                "description": "alanine aminotransferase (ALT)\naspartate aminotransferase (AST)\ntotal bilirubin \uff08TBIL\uff09\ndirect bilirubin (DBIL)\nserum cholinesterase (CHE)\nalbumin (ALB)", 
                "measure": "liver function", 
                "safety_issue": "Yes", 
                "time_frame": "whinin 7 days before transplantation, 1,3 and 6 months after transplantation"
            }, 
            {
                "description": "temperature\npulse\nblood pressure", 
                "measure": "vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "1, 2 and 3 days after transplantation"
            }, 
            {
                "measure": "incidence of hepatocellular carcinoma", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3 and 6 months after transplantation"
            }, 
            {
                "measure": "mortality", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3 and 6 months after transplantation"
            }
        ], 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}